Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

P
Pacas, Pavel

Department of Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol
(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Pavel Pacas
Favorite
Pacaud, Camille

University Hospitals of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Camille Pacaud
Favorite
Pagnano, Maria Elisabetta

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Maria Elisabetta Pagnano
Favorite
Palmerini, Emanuela

IRCCS Istituto Ortopedico Rizzoli
(P 41) PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT
Emanuela Palmerini
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Emanuela Palmerini
Favorite
Palmerini, Emanuela

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Emanuela Palmerini
Favorite
Palmerini, Emanuela

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Emanuela Palmerini
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Emanuela Palmerini
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Emanuela Palmerini
Favorite
Pal, Rahul

6Department of Radiology, Massachusetts General Hospital
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Rahul Pal
Favorite
Pal, Tuya

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Tuya Pal
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Tuya Pal
Favorite
Pan, Irene

United BioSource LLC
(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
Irene Pan
Favorite
Pan, Minggui

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Minggui Pan
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Minggui Pan
Favorite
Pannella, Micaela

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Micaela Pannella
Favorite
Pan, Qiuzhong

Sun Yat-sen University Cancer Center
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Qiuzhong Pan
Favorite
Pantaleo, Maria Abbondanza

Università di Bologna
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Maria Abbondanza Pantaleo
Favorite
Paoli, Albit

MedStar Georgetown Cancer Institute
(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Albit Paoli
Favorite
Paoluzzi Tomada, Elisa

IRCCS Humanitas Research Hospital
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Elisa Paoluzzi Tomada
Favorite
Papagelopoulos, Panayiotis

First Department of orthopaedic surgery, National and Kapodistrian University of Athens, Attikon University General Hospital
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Panayiotis Papagelopoulos
Favorite
Papai, Emily

Fox Chase Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Emily Papai
Favorite
Papakonstantinou, Andri

Karolinska University Hospital
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Andri Papakonstantinou
Favorite
Parafioriti, Antonina

Istituto Ortopedico Gaetano Pini
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Antonina Parafioriti
Favorite
Park, Ben

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Ben Park
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Ben Park
Favorite
Park, Byung

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Byung Park
Favorite
Park, Jay Hoon

Seoul National University Hospital
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Jay Hoon Park
Favorite
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Jay Hoon Park
Favorite
Park, Julie

St. Jude Children's Research Hospital
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Julie Park
Favorite
Parra, Adrian

University of Miami Miller School of Medicine
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Adrian Parra
Favorite
Pasquali, Sandro

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Sandro Pasquali
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Sandro Pasquali
Favorite
Patel, Abhijit

Yale University School of Medicine
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Abhijit Patel
Favorite
Patel, Anand

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Anand Patel
Favorite
Patel, Anmol

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Anmol Patel
Favorite
Patel, Neel

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Neel Patel
Favorite
Patel, Neil

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Neil Patel
Favorite
Patel, Shalin Shreyaskumar

The University of Texas MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Shalin Shreyaskumar Patel
Favorite
Paternostro, Flavia

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Flavia Paternostro
Favorite
Patrizi, Sara

Ospedale Pediatrico Bambino Gesù
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Sara Patrizi
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Sara Patrizi
Favorite
Pattabhi, Sowmya

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Sowmya Pattabhi
Favorite
Paudel, Amrit

University of Miami Sylvester Comprehensive Cancer Center
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Amrit Paudel
Favorite
Pauli, Chantal

University Hospital Zurich, Switzerland
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Chantal Pauli
Favorite
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Chantal Pauli
Favorite
Pautier, Patricia

Gustave Roussy
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Patricia Pautier
Favorite
Pavisic, Jovana

Memorial Sloan Kettering Cancer Center
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Jovana Pavisic
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Jovana Pavisic
Favorite
Peabody, Terrance

Northwestern Memorial Hospital
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Terrance Peabody
Favorite
Peairs, Emily
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Emily Peairs
Favorite
Pecchia, Leandro

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Leandro Pecchia
Favorite
Pedace, Lucia

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Lucia Pedace
Favorite
Pedgaonkar, Aditi

Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Aditi Pedgaonkar
Favorite
Pelles, Sharon

Oncology, Barzilai Medical Center, Ashkelon
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Sharon Pelles
Favorite
Pendilli, Sebastiano

IRCCS Humanitas Research Hospital
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Sebastiano Pendilli
Favorite
Penel, Nicolas

Centre Oscar Lambret
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Nicolas Penel
Favorite
Peng, Ruiqing

Sun Yat-sen University Cancer Center
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Ruiqing Peng
Favorite
Pennacchioli, Elisabetta

Istituto Europeo di Oncologia
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Elisabetta Pennacchioli
Favorite
Penninga, Luit

Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet
(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Luit Penninga
Favorite
(P 385) SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM
Luit Penninga
Favorite
(P 386) SOLITARY FIBROUS TUMOUR: A DANISH SAMPLE FROM 2013 – 2018
Luit Penninga
Favorite
(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Luit Penninga
Favorite
Perano, Vittoria

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Vittoria Perano
Favorite
Perati, Shruthi

National Institutes of Health, National Cancer Institute, Surgical Oncology Program
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Shruthi Perati
Favorite
Percio, Stefano

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Stefano Percio
Favorite
Peretz Soroka, Hagit

Princess Margaret Cancer Centre
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Hagit Peretz Soroka
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Hagit Peretz Soroka
Favorite
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Hagit Peretz Soroka
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Hagit Peretz Soroka
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Hagit Peretz Soroka
Favorite
Pérez Capó, Marina

Health Research Institute of the Balearic Islands
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Marina Pérez Capó
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Marina Pérez Capó
Favorite
Pérez-Albert, Maria Paula

Vall d´Hebrón University Hospital
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Maria Paula Pérez-Albert
Favorite
Perkins, Callum

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Callum Perkins
Favorite
Perry, Curtis

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Curtis Perry
Favorite
Perry, Kyle

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Kyle Perry
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Kyle Perry
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Kyle Perry
Favorite
Pestana, Roberto

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Roberto Pestana
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Roberto Pestana
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Roberto Pestana
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Roberto Pestana
Favorite
Peta, Giuliano

Radiology, IRCCS Istituto Ortopedico Rizzoli
(P 41) PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT
Giuliano Peta
Favorite
Petersen, Michael

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Michael Petersen
Favorite
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Michael Petersen
Favorite
(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Michael Petersen
Favorite
Peterson, Susan

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Susan Peterson
Favorite
Philibert, Helene

University of Saskatchewan
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Helene Philibert
Favorite
Phillips, McLeod

Atlantic Health System
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
McLeod Phillips
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
McLeod Phillips
Favorite
Piątkowski, Jakub

Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Jakub Piątkowski
Favorite
Pierini, Michela

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Michela Pierini
Favorite
Pignochino, Ymera

University of Turin, School of Medicine,Candiolo Cancer Institute, FPO-IRCCS
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Ymera Pignochino
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Ymera Pignochino
Favorite
Pike, William

Atropos Health
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
William Pike
Favorite
Pilat, Mary

Karmanos Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Mary Pilat
Favorite
Pileri, Stefano

UniversitY of Bologna
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Stefano Pileri
Favorite
Pinkas, Jan

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Jan Pinkas
Favorite
Pinnaduwage, Dushanthi

University of Toronto
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Dushanthi Pinnaduwage
Favorite
Pinto, Navin

Children's Hospital of Colorado
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Navin Pinto
Favorite
Piperno-neumann, Sophie

Institut Curie
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Sophie Piperno-neumann
Favorite
Pires de Camargo, Veridiana

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
Pischel, Kristin

Sarcoma Oncology Center
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Kristin Pischel
Favorite
Planas-Paz, Lara

Department of Pathology and Molecular Pathology USZ
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Lara Planas-Paz
Favorite
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Lara Planas-Paz
Favorite
Planchamp, François

Institut Bergonié, Bordeaux (France);
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
François Planchamp
Favorite
Pliego-Mendieta, Alicia

Department of Pathology and Molecular Pathology USZ
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Alicia Pliego-Mendieta
Favorite
Pohly Jeppesen Thorn, Andrea

Musculoskeletal Tumor Section, Copenhagen University Hospital, Rigshospitalet
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Andrea Pohly Jeppesen Thorn
Favorite
Pollack, Seth

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology, Chicago
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Seth Pollack
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Seth Pollack
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Seth Pollack
Favorite
Pollock, Raphael

The James Cancer Hospital / The Ohio State University
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Raphael Pollock
Favorite
Pollock, Raphael E.

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Raphael E. Pollock
Favorite
Post, Carl

Oregon Health and Science University
(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Carl Post
Favorite
Postovsky, Sergey

Emek General Hospital
(P 312) RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD
Sergey Postovsky
Favorite
Poulson, Trevor

Rush University Medical Center
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Trevor Poulson
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Trevor Poulson
Favorite
Powers, Benjamin

University of Kansas Cancer Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Benjamin Powers
Favorite
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Benjamin Powers
Favorite
(P 221) 8+ YEARS OF IMMUNOTHERAPY FOR METASTATIC ALVEOLAR SOFT PART SARCOMA
Benjamin Powers
Favorite
Pozas, Javier

The Royal Marsden NHS Foundation Trust, London- UK
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Javier Pozas
Favorite
Pracha, Sahal

The Ohio State University James Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Sahal Pracha
Favorite
Prados, Elena

Son Espases University Hospital
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Elena Prados
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Elena Prados
Favorite
Pratilas, Christine

Johns Hopkins University School of Medicine
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Christine Pratilas
Favorite
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Christine Pratilas
Favorite
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Christine Pratilas
Favorite
Preisler, Louise

Rigshospitalet
(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Louise Preisler
Favorite
(P 385) SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM
Louise Preisler
Favorite
Pretorius, Lauren

Campaigning for Cancer
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Lauren Pretorius
Favorite
Price, Lucy

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Lucy Price
Favorite
Prigmore, Brian

Oregon Health & Science University
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Brian Prigmore
Favorite
Primeaux, Sharon

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Sharon Primeaux
Favorite
Pringle, Toni

School of Natural and Environmental Sciences, Newcastle University, UK
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Toni Pringle
Favorite
Prosser, Denise
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Denise Prosser
Favorite
Prudhomme, Nicolas

Centre Hospitalier Universitaire Sainte-Justine
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nicolas Prudhomme
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nicolas Prudhomme
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nicolas Prudhomme
Favorite
Pruimboom, Tim

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Tim Pruimboom
Favorite
Pruthi, Manish

Tata Memorial Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Manish Pruthi
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Manish Pruthi
Favorite
Przybyl, Joanna

McGill University
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Joanna Przybyl
Favorite
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Joanna Przybyl
Favorite
(P 112) MACHINE LEARNING ANALYSIS TO DEFINE CELL LINEAGE IN LEIOMYOSARCOMA
Joanna Przybyl
Favorite
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Joanna Przybyl
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Joanna Przybyl
Favorite
(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Joanna Przybyl
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Joanna Przybyl
Favorite
Psoinos, Charles

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Charles Psoinos
Favorite
Puls, Florian

Sahlgrenska University hospital
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Florian Puls
Favorite
Punturi, Nindo

Chordoma Foundation
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Nindo Punturi
Favorite
Puri, Ajay

Tata Memorial Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Ajay Puri
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Ajay Puri
Favorite
Pu, Tracey

Surgical Oncology, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Tracey Pu
Favorite
Puviidran, Vijitha

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Vijitha Puviidran
Favorite
Pyczek, Joanna

University of Calgary
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Joanna Pyczek
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Joanna Pyczek
Favorite